| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082751 | Drug Discovery Today: Technologies | 2011 | 7 Pages |
Abstract
Molecular imaging is becoming an indispensable part of clinical drug development. The presented review highlights few state-of-the-art examples that serve to illustrate specific points and discuss future directions of the use of positron emission tomography (PET) imaging in various phases of clinical drug development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Jan Marik, Sandra M. Sanabria Bohorquez, Simon-Peter Williams, Nicholas van Bruggen,